2353 related articles for article (PubMed ID: 33247152)
21. Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response.
Xu W; Liu Y; Zou X; Luo H; Wu W; Xia J; Chan MTV; Fang S; Shu Y; Wu WKK; Zhang L
Front Immunol; 2021; 12():785599. PubMed ID: 35058926
[TBL] [Abstract][Full Text] [Related]
22. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis.
Indenbaum V; Koren R; Katz-Likvornik S; Yitzchaki M; Halpern O; Regev-Yochay G; Cohen C; Biber A; Feferman T; Cohen Saban N; Dhan R; Levin T; Gozlan Y; Weil M; Mor O; Mandelboim M; Sofer D; Mendelson E; Lustig Y
PLoS One; 2020; 15(11):e0241164. PubMed ID: 33227020
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
[TBL] [Abstract][Full Text] [Related]
24. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
26. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
27. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
[TBL] [Abstract][Full Text] [Related]
28. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
Harrington WE; Trakhimets O; Andrade DV; Dambrauskas N; Raappana A; Jiang Y; Houck J; Selman W; Yang A; Vigdorovich V; Yeung W; Haglund M; Wallner J; Oldroyd A; Hardy S; Stewart SWA; Gervassi A; Van Voorhis W; Frenkel L; Sather DN
Cell Rep Med; 2021 Apr; 2(4):100253. PubMed ID: 33842901
[TBL] [Abstract][Full Text] [Related]
29. IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.
Tutukina M; Kaznadzey A; Kireeva M; Mazo I
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696374
[TBL] [Abstract][Full Text] [Related]
30. Dynamics of Antibodies to Various Antigens of the SARS-CoV-2 Coronavirus in Patients with Confirmed COVID-19 Infection.
Aleshkin AV; Novikova LI; Bochkareva SS; Kombarova SY; Lebedin YS; Vorob'ev AM; Mekhtiev ER; Zul'karneev ER; Laishevtsev AI; Karaulov AV
Bull Exp Biol Med; 2021 May; 171(2):230-233. PubMed ID: 34173107
[TBL] [Abstract][Full Text] [Related]
31. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
32. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
Front Immunol; 2020; 11():1936. PubMed ID: 32849650
[No Abstract] [Full Text] [Related]
33. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
Pisanic N; Randad PR; Kruczynski K; Manabe YC; Thomas DL; Pekosz A; Klein SL; Betenbaugh MJ; Clarke WA; Laeyendecker O; Caturegli PP; Larman HB; Detrick B; Fairley JK; Sherman AC; Rouphael N; Edupuganti S; Granger DA; Granger SW; Collins MH; Heaney CD
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33067270
[TBL] [Abstract][Full Text] [Related]
34. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
[TBL] [Abstract][Full Text] [Related]
35. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
Rockstroh A; Wolf J; Fertey J; Kalbitz S; Schroth S; Lübbert C; Ulbert S; Borte S
Emerg Microbes Infect; 2021 Dec; 10(1):774-781. PubMed ID: 33830901
[TBL] [Abstract][Full Text] [Related]
36. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
Front Immunol; 2021; 12():724763. PubMed ID: 34489978
[TBL] [Abstract][Full Text] [Related]
37. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
[TBL] [Abstract][Full Text] [Related]
38. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study.
Shi D; Weng T; Wu J; Dai C; Luo R; Chen K; Zhu M; Lu X; Cheng L; Chen Q; Liu F; Wu Z; Wu H; Jin C; Guo M; Chen Z; Wu N; Yao H; Zheng M
Front Immunol; 2021; 12():708184. PubMed ID: 34354712
[TBL] [Abstract][Full Text] [Related]
39. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.
Sun B; Feng Y; Mo X; Zheng P; Wang Q; Li P; Peng P; Liu X; Chen Z; Huang H; Zhang F; Luo W; Niu X; Hu P; Wang L; Peng H; Huang Z; Feng L; Li F; Zhang F; Li F; Zhong N; Chen L
Emerg Microbes Infect; 2020 Dec; 9(1):940-948. PubMed ID: 32357808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
